Literature DB >> 10188981

Effects of angiotensin II receptor blockade on proximal fluid uptake in the rat kidney.

M L Smart1, S Hiranyachattada, P J Harris.   

Abstract

Angiotensin II has a well described dose-dependent biphasic action on proximal tubule fluid uptake, although the concentration and effect of endogenous luminal angiotensin II remain controversial. Shrinking split-droplet micropuncture was used to examine the fluid uptake in response to the luminal application of three AT1 antagonists (losartan, EXP3174, candesartan). Addition of losartan at 10(-8) M decreased fluid uptake rate (Jva) by 17.5+/-2.2% (P<0.05). Luminal addition of EXP3174 at concentrations between 10(-9)-10(-5) M caused a dose-dependent decrease in fluid uptake, with a maximum decrease of 41.0+/-9.5% (P<0.01) at 10(-6) M. Candesartan also decreased fluid uptake, by 21.9+/-4.9% (P<0.05) at 10(-8) M and 23.6+/-5.5% (P<0.05) at 10(-5) M. All three antagonists at a low concentration (10(-8) M) decreased fluid uptake. EXP3174 and candesartan at a higher concentration (10(-5) M) also decreased fluid uptake in contrast to the previously reported effect of losartan. We conclude that the endogenous concentration of antiotensin II in the proximal luminal fluid is low and exerts a stimulatory effect on fluid absorption. Losartan at concentrations greater than 10(-6) M may have a non-selective action on fluid uptake.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188981      PMCID: PMC1565867          DOI: 10.1038/sj.bjp.0702366

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.

Authors:  P C Wong; W A Price; A T Chiu; J V Duncia; D J Carini; R R Wexler; A L Johnson; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

2.  Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist.

Authors:  M H Xie; F Y Liu; P C Wong; P B Timmermans; M G Cogan
Journal:  Kidney Int       Date:  1990-09       Impact factor: 10.612

3.  Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.

Authors:  A T Chiu; D E McCall; W A Price; P C Wong; D J Carini; J V Duncia; R R Wexler; S E Yoo; A L Johnson; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

4.  Mechanism of angiotensin II action on proximal tubular transport.

Authors:  T Wang; Y L Chan
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

5.  Digital image capture and analysis for split-drop micropuncture.

Authors:  P J Harris; M Cullinan; D Thomas; T O Morgan
Journal:  Pflugers Arch       Date:  1987-05       Impact factor: 3.657

6.  Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney.

Authors:  P J Harris; J A Young
Journal:  Pflugers Arch       Date:  1977-01-17       Impact factor: 3.657

7.  Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat.

Authors:  M G Seikaly; B S Arant; F D Seney
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

8.  Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules.

Authors:  V L Schuster; J P Kokko; H R Jacobson
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

9.  Distribution of angiotensin II receptor subtypes in rat and human kidney.

Authors:  L A Sechi; E F Grady; C A Griffin; J E Kalinyak; M Schambelan
Journal:  Am J Physiol       Date:  1992-02

10.  The role of endogenous angiotensin II in the regulation of renal haemodynamics and proximal fluid reabsorption in the rat.

Authors:  J Zhuo; D Thomas; P J Harris; S L Skinner
Journal:  J Physiol       Date:  1992       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.